The United States Court of
Appeals for the Federal Circuit
upheld the district court’s
judgement that producing generic
versions of Lyrica (pregabalin)
would infringe upon Pfizer’s patent.
The drug is used to treat epileptic
seizures and neuropathic pain, and
the ruling meant Lyrica generics
must not be sold before Dec 2018,
according to court documents.
Pfizer brought the suit against
various groups including Teva
Pharmaceuticals USA, Lupin
Pharmaceuticals and Alphapharm
Pty Ltd, after they filed an
application to the US Food and
Drug Administration seeking to
market a generic version of Lyrica.
To view the ruling, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 10 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Feb 14
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.